Vertex Newswire

Comprehensive Real-Time News Feed for Vertex.

Results 1 - 20 of 313 in Vertex

  1. Monday Deadline: Levi & Korsinsky, LLP Reminds Investors of Class...Read the original story w/Photo

    15 hrs ago | Business Wire

    Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Vertex Pharmaceuticals Incorporated securities between May 7, 2012 and May 29, 2012.

    Comment?

  2. Cystic Fibrosis Letdown ExplainedRead the original story w/Photo

    Thursday | Chemical & Engineering News

    ... to its proper place, and Kalydeco would then boost ion flow. Phase III clinical trial results support this idea. Vertex Pharmaceuticals, maker of Kalydeco, reported on June 24 that a combination of Kalydeco and its corrector molecule, lumacaftor, ...

    Comment?

  3. CIS Executive Breakfast Reengages AMP Final Rule and ACA PreparationRead the original story

    Wednesday | PressReleasePoint

    Industry experts from CIS and Vertex Pharmaceuticals will discuss their experiences preparing for the AMP Final Rule and other Affordable Care Act changes to date on July 29 in Boston.

    Comment?

  4. Cystic Fibrosis Drug Combination May Be Counteracting ItselfRead the original story w/Photo

    Wednesday Jul 23 | Chemical & Engineering News

    ... to its proper place, and Kalydeco would then boost ion flow. Phase III clinical trial results support this idea. Vertex Pharmaceuticals, maker of Kalydeco, reported on June 24 that a combination of Kalydeco and its corrector molecule, lumacaftor, ...

    Comment?

  5. Tests suggest limitations to Vertex's cystic fibrosis treatmentRead the original story w/Photo

    Wednesday Jul 23 | Boston.com

    Investors and patients were exuberant last month when Vertex Pharmaceuticals released results from clinical trials showing that cystic fibrosis patients' lung function improved on an experimental two-drug regimen.

    Comment?

  6. Investor Alert: Class Action Lawsuit Against Vertex Pharmaceuticals...Read the original story

    Wednesday Jul 23 | Customer Interaction Solutions

    ... for the District of Massachusetts on behalf of all purchasers of the common stock of Pharmaceuticals Incorporated ("Vertex" or the "Company") (NASDAQ:VRTX) between May 7, 2012 and May 29, 2012, inclusive (the "Class Period"). is engaged in ...

    Comment?

  7. Why it's so hard to develop a drug for cystic fibrosisRead the original story w/Photo

    Wednesday Jul 23 | Science

    ... gets to the cell surface like it's supposed to, but it's closed up tight and can't function. VX-770, designed by Vertex Pharmaceuticals, opens the protein into the right configuration so it can do its job. VX-770 was approved in 2012 for patients ...

    Comment?

  8. New cystic fibrosis drug shows great promiseRead the original story w/Photo

    Monday Jul 21 | Canada.com

    ... not revealed, the drug can cost up to $300,000 annually for patients in the United States. The drug was developed by Vertex Pharmaceuticals, which is headquartered in Boston. Kalydeco is among the first cystic fibrosis treatments to be released ...

    Comment?

  9. Codexis: $25m GSK tech accord could be catalyst for more Big Pharma dealsRead the original story w/Photo

    Tuesday Jul 15 | In-PharmaTechnologist.com

    ... . Previously, Codexis has cited hepatitis C as a key driver both as a result of the Merck deal and its work with Vertex Pharmaceuticals ( page 15 ). However, changing market dynamics mean this is no longer the case according to Nicols. " The ...

    Comment?

  10. New cystic fibrosis drug working for Greenwood manRead the original story w/Photo

    Saturday Jul 19 | The Chronicle Herald

    ... a year. Vallillee, a longtime fundraiser and advocate for cystic fibrosis patients, was approved last spring by Vertex Pharmaceuticals of Boston, the drug manufacturer, under its compassionate care program. "Things are incredible,'' he said in an ...

    Comment?

  11. Fed: Beware of social media, biotech stocksRead the original story w/Photo

    Tuesday Jul 15 | WTVR Richmond

    ... pulled back, with the Nasdaq Composite - home to many biotech and social media stocks - shedding 1%. Just look at Vertex Pharmaceuticals, which dropped 2% on the Fed comments. This biotech stock carries a forward price-to-earnings (P/E) ratio of ...

    Comment?

  12. Codexis: $25m GSK tech accord could be catalyst for more Big Pharma dealsRead the original story w/Photo

    Tuesday Jul 15 | In-PharmaTechnologist.com

    ... . Previously, Codexis has cited hepatitis C as a key driver both as a result of the Merck deal and its work with Vertex Pharmaceuticals ( page 15 ); however, changing market dynamics mean this is no longer the case according to Nicols. " The ...

    Comment?

  13. Vertex Pharmaceuticals (MA) To Announce Second Quarter 2014 Financial Results On July 29Read the original story

    Tuesday Jul 15 | BioSpace

    Vertex Pharmaceuticals Incorporated will report its second quarter 2014 financial results on Tuesday, July 29, 2014 after the financial markets close.

    Comment?

  14. Investor Alert: Glancy Binkow & Goldberg LLP Reminds Investors of the ...Read the original story

    Tuesday Jul 15 | Business Wire

    Glancy Binkow & Goldberg LLP reminds investors of Vertex Pharmaceuticals Incorporated that all purchasers of Vertex common stock between May 7, 2012 and May 29, 2012, inclusive have until July 28, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.

    Comment?

  15. Atlantis ComputingR Announces Record 1H Bookings, Appoints new CEO;...Read the original story

    Tuesday Jul 15 | Hispanic Business

    ... storage management, and virtualisation software companies. Jason has previously served in the CEO roles at Vertex, a , a publicly listed managed service provider. "Atlantis was started with a vision of a future where intelligent and agile Software ...

    Comment?

  16. Atlantis Computing(R) Announces Record 1H Bookings, Appoints New CEORead the original story

    Monday Jul 14 | Information Technology

    ... storage management, and virtualization software companies. Jason has previously served in the CEO roles at Vertex, a $150 million revenue IT services provider to North American utilities; Acronis, a $150 million revenue backup & recovery software ...

    Comment?

  17. Up 33%: Is Vertex Pharmaceuticals Stock Overpriced?Read the original story

    Monday Jul 14 | The Motley Fool

    ... After 24 weeks, the phenomenal performance of patients who took the ivacaftor/lumacaftor made it clear that Vertex had another blockbuster product in CF. Across both trials, treated patients had 30-39% reductions in pulmonary exacerbations relative ...

    Comment?

  18. Vertex to Announce Second Quarter 2014 Financial Results on July 29Read the original story

    Monday Jul 14 | Business Wire

    Vertex Pharmaceuticals Incorporated will report its second quarter 2014 financial results on Tuesday, July 29, 2014 after the financial markets close.

    Comment?

  19. Nasdaq 100 Movers: VRTX, MYLRead the original story w/Photo

    Monday Jul 14 | Forbes.com

    ... Year to date, Mylan registers a 18.8% gain. And the worst performing Nasdaq 100 component thus far on the day is Vertex Pharmaceuticals (VRTX), trading down 1.6%. Vertex Pharmaceuticals is showing a gain of 31.2% looking at the year to date ...

    Comment?

  20. 1 Drug More Important to Gilead Than SovaldiRead the original story w/Photo

    Friday Jul 11 | The Motley Fool

    ... indication may continue during the next few years. Only three years ago, investors were clamoring to buy shares of Vertex Pharmaceuticals following the launch of Incivek, its blockbuster hepatitis C drug. However, doctors who were anticipating ...

    Comment?